Imperial Innovations Group plc acts as a holding company. It acts as a technology transfer business taking the inventions from Imperial College and commercializing them either through licensing or by forming a technology company. Its principal activities are technology commercialization and investments.
24/05/12
Director Dealings01/05/12
Director Dealings23/04/12
Half year results26/03/12
Investment in portfolio company26/03/12
Notice of Results21/03/12
Directorate Change08/03/12
Circassia Phase II Clinical Trial Success13/02/12
Investment in portfolio company14/12/11
Result of AGM06/12/11
Investment in new start-up07/12/10
Imperial Innovations raises £140 mln to fund new investments20/08/10
Imperial Innovations ups stake in Plaxica and Nexeon01/06/10
Imperial Innovations sells Respivert for £9.5 million02/03/10
Imperial Innovations partner MET sold to Evonik Industries for 4.5m17/02/10
Imperial Innovations invests further £2 million in drug stabilisation company PolyTherics27/01/10
Imperial Innovations grants exclusive IP license to Novartis for Meningitis B vaccine21/09/09
Imperial Innovations leads £1.95 million funding round for Cell Medica01/09/09
Imperial Innovations commits £1.5 million to Molecular Vision’s research
Copyright © Proactiveinvestors.co.uk, 2012. All Rights Reserved Design & Development: Tehnicom Computers
